Navigation Links
Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy
Date:9/10/2013

itute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to http://www.broadinstitute.org.

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors in
'/>"/>

SOURCE Bayer HealthCare
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
2. FDA Advisory Committee Unanimously Recommends Approval Of Bayers Riociguat In Two Pulmonary Hypertension Indications
3. Statement: Bayer Mourns Passing of Senator Frank Lautenberg
4. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
5. Bayer Employee Named Rising Star by Healthcare Businesswomens Association
6. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
9. U.S. FDA Grants Priority Review to Bayers Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Bayer Consumer Care Voluntarily Recalls 56 Lots of BRONKAID Caplets Dual Action Formula due to Product Labeling Error
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... will participate in the upcoming 27 th Annual ... Dana Point, CA.  Dr. Michael ... Oramed, will present a corporate overview on March 10, ...
(Date:3/4/2015)... Mallinckrodt plc (NYSE: MNK ), a ... Global Healthcare Conference at the Loews Miami Hotel in ... 11, 2015. Mark Trudeau, President and Chief Executive Officer of ... to begin at 10:45 a.m. Eastern. Individuals ... webcast information on Mallinckrodt,s Investor Relations website ...
(Date:3/4/2015)... NEWARK, N.J. , March 4, 2015 /PRNewswire/ ... biopharmaceutical company developing innovative medicines for serious women,s ... 1 clinical program demonstrating that its lead product ... had predictable pharmacokinetics (PK), and that contraceptive efficacy ... by SYM-1219 administration. These results will ...
Breaking Medicine Technology:Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3Mallinckrodt to Present at Barclays Conference March 11 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5
... MedShape Solutions, Inc., the industry leader in innovative ... developed new, larger sizes of its ExoShape CL, ... simplifies and improves soft tissue graft fixation during ... comes after MedShape received the U.S. Food and ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced that ... the ongoing Phase Ia trial to test the safety of ... testing the drug in healthy volunteers for safety and tolerability. ... that stimulates new neuron growth in the hippocampus, an area ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
(Date:3/4/2015)... DC (PRWEB) March 04, 2015 ... additional discussion leaders for its upcoming fifth annual ... in Paris, France. The event this year will ... more than 20 of the field’s leading companies ... bring together top executives and clinical researchers from ...
(Date:3/4/2015)... March 04, 2015 Jeannie Mai, TV personality, ... Real” graces the cover of the print publication. Mai embraces ... choose organic when shopping for clothes and personal care products. ... up about her commitment to an organic diet. She mentions, ... not only in gymnastics, but also now as I’m a ...
(Date:3/4/2015)... 2015 i2i Systems Population Health ... Chase Brexton Health Care, a 35-year-old Maryland-based community ... Brexton provides comprehensive primary care, behavioral health and ... seven clinics in the greater Baltimore area of ... records, the organization has always focused on providing ...
(Date:3/4/2015)... A new dieting routine, called the feast ... extending life. Studies conducted by the University ... can help extend life by increasing anti-oxidant production. While ... benefits, many suffering from obesity are already experiencing life ... As an alternative to the new Feast and Famine ...
(Date:3/4/2015)... Nitrosigine®, a patented complex of bonded arginine ... products, is hosting the Nitrosigine Pump Challenge at the ... at The Arnold Sports Festival in Columbus, Ohio. The ... 8, 2015. , Nitrosigine is a patented ingredient ... notification status; now affirmed as GRAS.^ It has been ...
Breaking Medicine News(10 mins):Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3
... conference,focusing on the future of healthcare will convene ... Summit will present an opportunity for leaders from,around ... and future seismic,"tremors" in the healthcare industry in ... make the industry virtually unrecognizable in,the coming years., ...
... Corporation (Nasdaq: HLTH ) and its approximately 83% owned ... they will release,their respective financial results for the three months ... May 6, 2008. The Companies,will host a conference call at ... Investors can access the call via webcast at http://www.hlth.com ...
... Medicine Led by Simmons School for Health,Studies, BOSTON, ... (Dietary Approaches to Stop Hypertension), which is high in,fruits ... risk of coronary heart disease and stroke, according to ... Internal Medicine., The study indicates for the first ...
... amount had almost half the risk of needing to start ... with naturally high levels of the antioxidant urate in their ... than those with lower levels do, a new report says. ... Archives of Neurology , support early laboratory studies about ...
... DASH diet cuts cardiovascular risk, studies find , , MONDAY, ... additional benefits of widely used measures aimed at preventing ... the DASH diet for blood pressure control lowers the ... , The statin study wasn,t intended to measure the ...
... Americas Baby Boomer generation, arthritis is a growing ... common joint disease currently afflicts over 20 million ... aggravate matters, arthritis is also prevalent among the ... adult population. Fortunately, treating the pain and disability ...
Cached Medicine News:Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Risk of Women's Heart Attack or Stroke Appears to Be Lowered by 'DASH' Diet 2Health News:Elevated Urate Levels May Slow Parkinson's in Men 2Health News:New Benefits From Old Heart Measures 2Health News:New Benefits From Old Heart Measures 3Health News:Study shows increase of hip and knee replacements in the US 2Health News:Study shows increase of hip and knee replacements in the US 3
... are polypeptide hormones which belong to ... The TGF- superfamily is a large ... control many aspects of development, reproductive ... members incude TGF-s, bone morphogenetic proteins, ...
... Osteocalcin, also known as bone Gla protein, ... which is a major component of the ... by osteoblasts in bone, with a small ... hypertrophic chondrocytes [1]. During bone formation, newly ...
... Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) is ... which specifically binds and modulates the bioactivity ... of IGFBP-1 has not been completely defined, ... that IGFBP-1 may be involved in glucose ...
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
Medicine Products: